HX301
Undisclosed (CD47 target)
Preclinical/Phase 1Active
Key Facts
Indication
Undisclosed (CD47 target)
Phase
Preclinical/Phase 1
Status
Active
Company
About HanX Biopharmaceuticals
Clinical-stage Chinese biotech developing novel antibody therapies for oncology and immunology with multiple IND approvals.
View full company profile